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Background: Overexpression of autologous proteins can lead to the formation of autoantibodies and autoimmune
diseases. MHC class I polypeptide-related sequence A (MICA) is highly expressed in the enterocytes of patients with
celiac disease, which arises in response to gluten. The aim of this study was to investigate anti-MICA antibody
formation in patients with celiac disease and its association with other autoimmune processes.
Methods: We tested serum samples from 383 patients with celiac disease, obtained before they took up a
gluten-free diet, 428 patients with diverse autoimmune diseases, and 200 controls for anti-MICA antibodies. All
samples were also tested for anti-endomysium and anti-transglutaminase antibodies.
Results: Antibodies against MICA were detected in samples from 41.7% of patients with celiac disease but in only
3.5% of those from controls (P <0.0001) and 8.2% from patients with autoimmune disease (P <0.0001). These
antibodies disappeared after the instauration of a gluten-free diet. Anti-MICA antibodies were significantly prevalent
in younger patients (P <0.01). Fifty-eight patients with celiac disease (15.1%) presented a concomitant autoimmune
disease. Anti-MICA-positive patients had a higher risk of autoimmune disease than MICA antibody-negative patients
(P <0.0001; odds ratio = 6.11). The risk was even higher when we also controlled for age (odds ratio = 11.69). Finally,
we found that the associated risk of developing additional autoimmune diseases was 16 and 10 times as high in
pediatric patients and adults with anti-MICA, respectively, as in those without.
Conclusions: The development of anti-MICA antibodies could be related to a gluten-containing diet, and seems to
be involved in the development of autoimmune diseases in patients with celiac disease, especially younger ones.
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Celiac disease (CD) was previously considered a relatively
rare pathology that appeared only in childhood, but is now
recognized as being a very common disease that can be di-
agnosed at any age [1,2]. Its most typical characteristics
are a strong genetic association with the human leukocyte* Correspondence: inmuno@hca.es
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article, unless otherwise stated.antigen (HLA) alleles DQ2 and DQ8 [3,4] and its triggering
by an environmental factor, the intake of gluten. The
soluble fraction of gliadin has been identified as the
cause of this intolerance, but many other gluten proteins
can be toxic in CD [5]. These proteins induce an inflamma-
tory process in the intestine of susceptible people, but in-
flammation regresses after elimination of gluten-containing
foods from the diet, leading to the recovery of the structure
and function of the mucosa [3].
Autoantibodies, especially those directed against the tis-
sue transglutaminase (tTG) enzyme, commonly appear inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this










n = 383 n = 428
Gender (female/male) 241/142 280/148 112/88
Mean age (SD) 22 (21.76) 39 (23.04) 23 (18.74)
Biopsy
Marsh I 7 (1.8%) - -
Marsh II 32 (8.3%) - -
Marsh IIIa 63 (16.4%) - -
Marsh IIIb 70 (18.3%) - -
Marsh IIIc 211 (55.1%) - -
HLA-DQ2-positivea 338 (89.2%)b 182 (42%) 44 (22%)
HLA-DQ8-positivea 42 (11.0%) 152 (35%) 18 (9%)
HLA-DQ2 and DQ8-negative 14 (3.6%) 136 (31.8%) 138 (69%)
Autoimmune diseases 58 (15.1%) 428 (100%) -
aIncludes DQ2-DQ8-positive patients; bP <0000.1; odds ratio = 24.19; 95%
confidence interval = 15.815, 36.997.
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sis of CD, but their role in the pathogenesis of the disease
remains controversial [7]. Several studies have suggested
that these antibodies are directly involved in the pathogen-
esis of CD. Zanoni et al. demonstrated the role of anti-TG2
antibodies in gut mucosal damage in patients with CD
[8]. Their study showed that these antibodies are able to
recognize an epitope that is common to TG2 and the
Toll-like receptor 4. This interaction leads to the activation
of the Toll-like receptor 4 pathway, an important initiator
of innate immunity. Other studies have shown that anti-
tTG antibodies may play an important role in epithelial cell
proliferation [9] and interfere with intestinal epithelial cell
adhesion [10]. Additionally, these autoantibodies disturb
angiogenesis and modulate vascular permeability in vitro
[11,12]. Taken together, these observations suggest that
future approaches to the study of CD should take the
role of humoral immunity into account.
Other mechanisms, such as the MHC class I polypeptide-
related sequence A (MICA)- Natural killer group 2, member
D (NKG2D) interaction, are directly involved in the
pathogenesis of the disease [13]. MICA and MICB show
homology with classical HLA-class I, but have no role in
antigen presentation. MICA and MICB are cell surface gly-
coproteins that are constitutively expressed in enterocytes
[14]. These proteins are ligands for the killer cell lectin-like
receptor subfamily K member 1, also known as NKG2D,
which is an activating receptor that is mainly expressed in
natural killer, CD8+ and γδTcells [15]. The MICA-NKG2D
interaction in natural killer cells induces their cytolytic cap-
acity, while in CD8+ Tcells it acts as a co-stimulatory signal
and complements antigen recognition by the T cell receptor
[16]. MICA is strongly expressed in the enterocytes of
patients with CD in response to the indirect toxic effect
of gluten [17]. Furthermore, MICA binds the NKG2D
receptor expressed on CD8+ intraepithelial lymphocytes
and activates these T cells. This activation causes damage
to the enterocytes, and could be the initiating event that
ultimately leads to villous atrophy.
The tissue damage and increased expression of MICA
may also induce the development of antibodies against
this molecule. In fact, anti-MICA autoantibodies have been
described in early-onset systemic lupus erythematosus
(SLE) [18]. Moreover, these antibodies have been implicated
in organ rejection in patients with renal [19-21] and cardiac
transplants [22,23].
To test the hypothesis that the CD-related changes in
gut mucosa may be associated with the development of
antibodies against MICA, we investigated the presence
of these antibodies in sera obtained from patients with
active CD. We also considered the possibility that
these antibodies play a role in the development of the
additional autoimmune diseases (ADs) customarily as-
sociated with CD [24].Methods
Study participants
A group of 383 patients diagnosed with CD (241 females,
142 males; mean age at diagnosis 22 ±21.96 years) by
the Gastroenterology and Paediatric Departments of two
Spanish and one Italian hospital between 2002 and 2012
were selected for this study. The diagnosis of CD was made
in accordance with the revised criteria of the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition [25,26] and World Gastroenterology Organisation
guidelines [27,28] In addition to clinical features, all patients
were positive for anti- tTG and/or anti-endomysium
antibodies. They also presented with a variable degree
of intestinal mucosal damage (Marsh I to Marsh IIIc),
before starting a gluten-free diet (GFD). A second serum
sample was obtained from all patients after at least one
year on a GFD. These samples were analyzed to establish
treatment compliance and to assess the influence of a
GFD on titers of anti-MICA antibodies.
All patients were typed for HLA-DQA1* and HLA-
DQB1* alleles. Similar to the prevalence noted in Caucasian
populations [29], 88% of the patients were HLA-DQ2+ and
11% were HLA-DQ8+. The clinical features of the patients
are illustrated in Table 1. Additionally, the various ADs
detected in these patients are listed in Table 2.
Another group of 428 patients (mean age 39 ± 3.04 years,
65.4% females) diagnosed for several ADs but without CD
were selected to establish whether the presence of anti-
MICA antibodies is related to CD or if they are another
serological marker of autoimmunity. The composition of
this group with respect to represented ADs is similar to
that for patients with CD and ADs (Table 2).






n = 58 n = 428
Type 1 diabetes 22 (37.9%) 106 (24.8%)
Autoimmune thyroiditis 9 (15.5%) 47 (11.0%)
Systemic lupus erythematosus 7 (12.1%) 92 (21.5%)
Rheumatoid arthritis 6 (10.3%) 51 (11.9%)
Pernicious anemia 3 (5.2%) 22 (5.1%)
Primary biliary cirrhosis 3 (5.2%) 17 (4.0%)
Juvenile idiopathic arthritis 1 (1.7%) 4 (1.0%)
Autoimmune hepatitis 3 (5.2%) 15 (3.5%)
Crohn’s disease 2 (3.4%) 40 (9.3%)
Ulcerative colitis - 9 (2.1%)
Mixed connective tissue disease 1 (1.7%) 1 (0.2%)
Addison’s disease - 3 (0.7%)
Sjögren’s syndrome 1 (1.7%) 21 (4.9%)
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23 ±18.74 years, 54% females) were selected for comparison
to patients with CD. Control individuals had no history
of intolerance to gluten or derivatives, iron deficiency,
anemia, or abnormalities in biochemical studies, and
were negative for anti-TG antibodies. To match healthy
controls and patients with CD by age, the proportion of
individuals aged ≤14 years was similar in both groups
(47% versus 52%). Children used as healthy controls were
selected from those with suspected allergic reactions who
were studied in the Allergology Department of Hospital
Universitario Central de Asturias.
The study was approved by the Ethics Committee of
each hospital (Regional Ethics Committee of Clinical
Research of Principado de Asturias; Ethical Committee of
S. Orsola Malpighi Hospital, University of Bologna; Ethical
Committee of Clinical Research from the Clinic Hospital,
University of Valladolid; Cantabria Ethics Committee for
Biomedical Research). All patients and controls or their
parents gave written informed consent.
Determining anti-endomysium and anti-transglutaminase
autoantibodies
Anti-endomysium antibodies were detected by indirect
immunofluorescence using tissue sections from monkey
esophagus (Biosystems, Barcelona, Spain). A titer of 1:10
or more was considered positive. Anti-tTG autoanti-
bodies were detected using an ELISA kit from Orgentec
(Mannheim, Germany). A value greater than 10 units
was considered positive. Patients’ sera were tested for
total immunoglobulins (Ig) to detect IgA deficiency. In
participants with IgA deficiencies, IgG equivalents of the
above tests were used.HLA and MICA typing
Genomic DNA from all patients was isolated and typed
for the HLA-DQ allele using DNA PCR amplification
with sequence-specific primers with the PROTRANSTM
Domino System HLA Celiac Disease kit (Protrans, Ketsch,
Germany). Additionally, MICA gene polymorphisms from
100 patients were typed with a LABType® SSO MICA
typing kit (One-Lambda, Los Angeles, CA, USA). All de-
terminations were done in accordance with the manufac-
turers’ protocols.
Anti-MICA antibody detection
MICA antibodies were identified by LABScreen® assays
(One-Lambda) using Luminex xMAP technology (Luminex
Corp., Austin, TX, USA), following the manufacturer’s
specifications. Serum samples from patient with CD and
controls were tested against MICA alleles using the
LABScreen® Mixed kit for general screening. Positive sera
were re-tested using LABScreen® MICA Single Antigen to
measure the specificity of the antibodies. The fluorescent
signal for each MICA allele-coated bead was measured
using LABScan 100TM Flow Cytometry and analyzed by
HLA-FusionTM software (One-Lambda). Antibodies against
MICA alleles were considered positive when the mean
fluorescent intensity (MFI) of each bead was above a
cut-off value of 500 in LABScreen® Mixed and 2000 in
LABScreen® MICA Single Antigen, as suggested by the
manufacturer. In all cases, anti-MICA antibodies detected
by this technique were of the IgG isotype.
Statistics
Descriptive analyses were used to characterize the study
population. The chi-square contingency test was used
to compare dichotomous variables and the unpaired t-test
was used to compare group differences of continuous
variables. Multivariate logistic regression was used to
model the variables that were significant in univariate
analyses or that were of clinical relevance. All analyses were
done using SPSS v.15.0. Values of P <0.05 were considered
significant in all cases.
Results
Anti-MICA autoantibodies are more prevalent in patients
with celiac disease
Our initial aim was to analyze anti-MICA antibodies in
sera obtained from patients diagnosed with CD and from
healthy controls. We found that their presence was clearly
associated with CD. Anti-MICA antibodies were detected
in 159 of 383 patients with CD (41.5%) compared with
3.5% of the healthy controls (P <0.0001; Table 3). In other
words, the odds of individuals with CD presenting anti-
MICA antibodies were 19 times those of healthy controls.
Next, to establish whether anti-MICA autoantibodies are
a characteristic of CD but not a frequent feature of other
Table 3 Prevalence of anti-MICA autoantibodies in







n = 383 n = 428 n = 200
Positive 159 (41.5%) 35 (8.2%)a 7 (3.5%)b
Negative 224 (58.5%) 393 (91.8%) 193 (96.5%)
aP <0.0001; odds ratio = 7.97; 95% CI = 5.38, 11.90. bP <0.0001; odds
ratio = 19.57; 95% confidence interval = 8.96, 42.74.
Table 4 Distribution of anti-MICA autoantibodies in
different patient groups included in the study by age
at diagnosis
Groups Anti-MICA n Mean SD Median P
All Negative 810 31.60 23.14 31 -
Positive 201 21.03 21.89 12 < 0.01
Healthy controls Negative 193 22.75 18.390 19 -
Positive 7 41.86 20.408 54 -
Patients with
celiac disease
Negative 224 24.85 22.320 23 -




Negative 393 39.81 22.88 41 -
Positive 35 31.86 23.85 26 -
Table 5 Risk of developing concomitant autoimmune
diseases in patients with celiac disease with respect to





n = 325 n = 58
Anti-MICA-positive 113 (34.8%) 46 (79.3%)
Anti-MICA-negative 212 (65.2%) 12 (20.7%)
P Odds ratio 95% confidence interval
Anti-MICA <0.0001 6.11 3.22, 11.59
Anti-MICAa <0.0001 11.69 5.49, 24.90
Risk associated with the presence of anti-MICA in all patients with CD.
aAdjusted by age at diagnosis.
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with the group who were diagnosed only with ADs. Our
results demonstrated that these autoantibodies were asso-
ciated with CD (41.5% in the CD group versus 8.2% in the
AD group; P <0.0001; odds ratio = 7.97; 95% confidence
interval: 5.38, 11.90). Anti-MICA antibodies were no
longer present in the additional sample of 75% of the
patients with CD who had been on a GFD for at least
one year. The second serum was positive for anti-tTG
antibodies in ten patients, six of whom had anti-MICA
antibodies (data not shown).
We compared the maximum MFI of anti-MICA auto-
antibodies with the values of anti-tTG ones, but found no
correlation between them (Additional file 1: Figure S1). The
distribution of maximum MFI among the different groups
of patients was also analysed, but revealed no statistically
significant differences (Additional file 1: Figure S2).
The specificities of the anti-MICA antibodies were
determined in 50 randomly selected patients, combining
Luminex single antigen analysis with MICA genotyping.
In all cases, the antibodies recognized self-MICA alleles.
Moreover, 22 patients also developed antibodies against
other MICA variants. The most frequent MICA antigen
detected was MICA*027, which corresponds to the MICA
A5.1 transmembrane polymorphism, which has previously
been associated with CD [29-31]. The allele was present in
74% of patients (data not shown).
Anti-MICA autoantibodies are related to age at diagnosis
Having identified the presence of anti-MICA antibodies,
we investigated whether other factors related to CD had
influenced their induction. First, we analyzed the influence
of patient age at diagnosis on the development of anti-
bodies (Table 4). Clearly, anti-MICA autoantibodies were
more prevalent at early ages: the mean age of people posi-
tive for anti-MICA was 21.03 years compared to 31.60 years
for people negative for anti-MICA; and the median age
was significantly lower in positive compared to negative
individuals (12 versus 31 years; P <0.01). The tendency of
antibodies to appear at a younger age was apparent in all
patient and control groups (Table 4).
No relationship was found between the presence of
anti-MICA antibodies and gender or the degree of the
Marsh lesion (see Additional file 1: Tables S1 and S2).The risk of developing additional autoimmune diseases in
patients with celiac disease is associated with anti-MICA
autoantibodies
Patients with CD had a higher incidence of additional
ADs, mainly type 1 diabetes [22,24,32]. The prevalence of
these diseases was relatively high in our population; 58
patients with CD (15.1%) were found to have concomitant
disease (Table 1). To identify possible risk factors related
to CD that could be involved in the development of these
pathologies, a multivariate analysis was performed. This
indicated that gender, HLA-DQ and Marsh type were not
associated with the presence of ADs in these patients.
However, patients with an additional autoimmune path-
ology were older, on average, than those who were affected
by CD alone (mean age, 36 ±20.18 versus 18 ±20.62 years,
P <0.001; data not shown).
We investigated the possible influence of anti-MICA
autoantibodies on the development of additional ADs
(Table 5). The majority of patients with CD and ADs were
positive for anti-MICA antibodies (79.3%; 46 out of 58),
whereas only 34.8% (113 out of 325) of patients affected
by CD alone had anti-MICA (Table 5), demonstrating that
the development of ADs in patients with CD was clearly
associated with the presence of anti-MICA autoantibodies
(P <0.0001; odds ratio = 6.11; 95% confidence interval:
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the risk associated with anti-MICA was notably higher
(P <0.0001; odds ratio = 11.69; 95% confidence interval:
5.49, 24.90).
As previously mentioned, ADs were more prevalent in
patients diagnosed with CD as adults, whereas anti-MICA
autoantibodies were more frequent in those diagnosed with
CD at pediatric age. Given the well-established influence of
age at diagnosis on the risk of developing concomitant ADs
due to anti-MICA, we decided to investigate the influence
of these autoantibodies in pediatric and adult patients. The
distribution in the two groups indicated that autoantibodies
were present in 74.4% of adult patients with concomitant
ADs, with an associated risk of 10.03 (P <0.0001), whereas
93.3% of pediatric patients with CD and an additional
autoimmune pathology had anti-MICA antibodies (P <0.01).
The risk associated with anti-MICA in children was 16.28,
which was higher than that in adult patients (Table 6).
Discussion
The mechanisms leading to systemic autoimmune aggres-
sion in patients with CD remain unknown. NKG2D and
their ligands could play a significant role in the development
of autoimmunity. In fact, these molecules are involved
in the pathogenesis of some ADs that are commonly asso-
ciated with CD, such as type 1 diabetes and rheumatoid
arthritis. For example, blockage of NKG2D in the pre-
diabetic stage in non-obese diabetic mice prevents the
development of diabetes [33]. In rheumatoid arthritis,
MICA and MICB are aberrantly expressed in pathological
tissue from affected joints and could be involved in the
continuation of the autoreactive process [34].
We found anti-MICA antibodies to be present in half
of the patients with untreated CD but in only 3.5% of
healthy controls. Moreover, anti-MICA antibodies were
present in most patients diagnosed with CD plus other
ADs, but were rare in patients solely with ADs. Further-
more, anti-MICA antibodies disappeared from most pa-
tients after a year on a GFD, similar to what occurs with
anti-tTG antibodies. These results imply that, generally,
the relationship between anti-MICA and associated ADsTable 6 Risk of developing concomitant autoimmune disease
presence of anti-MICA autoantibodies, according to age at di
Celiac disease only
Age groups Pediatric Adult
(n = 186) (n = 139)
Anti-MICA-positive 76 (40.9%) 26 (18.7%)




Risk associated with the presence of anti-MICA in pediatric (≤14 years) and adult (>is directly linked to CD rather than being a phenomenon
specifically associated with autoimmunity. However, as
previously mentioned, early-onset SLE may be an exception
to this pattern, since these antibodies have also been
described in this disease [18].
Previous studies of CD show that MICA protein is
overexpressed in enterocytes obtained from the damaged
mucosa of patients [13,17]. A high level of MICA expression
seems to promote mucosal damage by infiltrating intrae-
pithelial CD8+ T lymphocytes, which express the MICA
receptor, NKG2D. In fact, other authors have suggested
that overexpression of MICA could be an initiating event
in the progression of mucosal damage [35-37]. In the early
phase of CD, some gluten-derived peptides, which have
been characterized as non-immunogenic, are directly
involved in increasing expression of MICA and IL-15.
These ‘toxic’ peptides activate the innate immunity through
an unknown pathway, leading to the destruction of the gut
mucosa [35]. As has been demonstrated in other inflam-
matory processes, massive cellular destruction may be
involved in the development of autoantibodies [38]. In
CD, an initially higher level of expression of MICA due
to gluten-derived peptides followed by the destruction
of enterocytes by intraepithelial lymphocytes could trigger
the subsequent development of anti-MICA antibodies in
susceptible individuals.
The fact that fewer than half of patients with CD have
anti-MICA prevents the use of this antibody as a diagnos-
tic marker. However, the greater prevalence of these auto-
antibodies in patients with additional ADs observed in our
study implies that anti-MICA antibodies might be use-
ful for predicting the risk of AD development. ADs are
diseases that are frequently associated with CD. Several
studies have found a close association between a long
period of gluten exposure [15,39] and a common gen-
etic background, although others found no relationship
between ADs and prolonged gluten intake in CD [40].
We found that ADs in our group of patients were more
frequent in adults than in the young, but this could be
related to the established effect of age on the prevalence
of these diseases, rather than due to the duration of glutens in patients with celiac disease with respect to the
agnosis
Celiac disease with autoimmune diseases
Pediatric Adult
(n = 15) (n = 43)
14 (93.3%) 32 (74.4%)
1 (6.7%) 11 (25.6%)
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bodies with the presence of additional ADs is substantially
modified by age. Surprisingly, although ADs are more
frequent in adults with CD, the risk associated with anti-
MICA antibodies of developing concomitant AD is clearly
greater in childhood, so the determination of these
autoantibodies may be very useful in clinical practice
to establish the risk in children. In our study, only one
pediatric patient with ADs was negative for anti-MICA
autoantibodies. In children, CD and other ADs are usually
more aggressive processes than in adults. In CD, this could
result in increased expression of MIC molecules in younger
patients, which would favor the generation of autoanti-
bodies. The presence of anti-MICA autoantibodies could
augment tissue destruction and lead to the early develop-
ment of ADs. As mentioned previously, Dai et al. also
demonstrated the presence of anti-MICA autoantibodies
in 27 patients with juvenile-onset SLE [18]. Our group of
428 patients with AD included 92 diagnosed with SLE. Six
of these patients were classified as juvenile-onset SLE and
all had anti-MICA (data not shown). Although these anti-
bodies have not been directly implicated in the disease,
they might be an additional risk factor in the development
of SLE and an interesting biomarker in the diagnostic of
this disease in childhood.
Limitations
Anti-MICA autoantibodies were present in fewer than
half of patients with CD, which make them less useful
than other autoantibodies, such as anti-tTG or anti-
deamidated gliadin, as a diagnostic biomarker. More-
over, all patients included in the study were positive for
anti-tTG although the absence of these autoantibodies
does not discard the diagnosis of CD, especially in children.
Therefore, it would be of great interest to analyze anti-
MICA in a population of patients with CD patients who
do not have anti-tTG autoantibodies.
Another limitation of this study is the small number of
patients with CD and a concomitant AD, which is es-
pecially relevant in the group of pediatric patients.
Conclusions
We have shown here that the development of anti-MICA
antibodies is associated with a gluten-containing diet in
patients with CD. In addition, anti-MICA antibodies are
apparently related to the development of ADs, especially
in younger patients although the number of individuals
in this study group was small. The determination of these
autoantibodies might be less suitable than others for the
diagnosis of the disease, but it could be very useful in clin-
ical practice for predicting the development of associated
ADs in patients with CD.
The mechanism by which these antibodies could influ-
ence the development of autoimmunity might be relatedto direct tissue damage, the activation of cellular immunity,
or another mechanism similar to that demonstrated for
anti-tTG in other studies [8-12]. Further work is needed to
establish the role and significance of these autoantibodies
in CD and, possibly, in other ADs such as SLE, especially in
patients with a young age of onset.Additional file
Additional file 1: Figure S1. Titration curves of anti-tTG autoantibodies
and anti-MICA autoantibodies in three representative patients with CD.
Figure S2. Dot box plot representing the distribution of maximum MFI
in the distinct groups of patients. No comparisons exhibited statistically
significant differences between the groups. Table S1. (A) Distribution of
MICA in patients with CD according to gender. (B) Distribution of genders
in patients with CD according to the presence or absence of anti-MICA
autoantibodies. Table S2. (A) Distribution of genders in patients with CD
according to the presence or absence of anti-MICA autoantibodies.
(B) Severity of mucosal lesion (Marsh classification) in patients with CD
according to the presence or absence of anti-MICA autoantibodies.Abbreviations
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